Financial review Another strong year for Shire with 12% growth in product sales and 14% growth in Non GAAP earnings which have driven particularly strong cash generation.
Graham Hetherington Chief Financial officer Revenues are derived primarily from two sources sales of the Overview Companys own products and royalties: Shire is a leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
The Q 94% 2011: 93% of total revenues are derived from product Company has grown through acquisition, completing a series of sales, of which 64% 2011: 66% are within SP, 32% 2011: 31% major transactions that have brought therapeutic, geographic and are within HGT and 4% 2011: 3% are within RM: and pipeline growth and diversication.
The Company will continue to Q 5% of total revenues are derived from royalties 2011: 6%.
evaluate companies, products and pipeline opportunities that offer a good strategic t and have the potential to deliver demonstrable The markets in which the Company conducts its business are value to all of the Companys stakeholders: patients, physicians, highly competitive and highly regulated.
policy makers, payors, investors and employees.
There is increasing legislation both in the US and the rest of the Substantially all of the Companys revenues, expenditures and world which is placing downward pressure on the net pricing of net assets are attributable to the R&D, manufacture, sale and pharmaceutical products and medical devices.
For example the distribution of pharmaceutical products within three reportable US government passed healthcare reform legislation in 2010 which segments: SP, HGT and RM.
The Company also earns royalties included an increase in Medicaid rebate rates and extended where Shire has out-licensed products to third parties which are Medicaid rebates to those products provided through Medicaid recorded as revenues.
The legislation also imposed excise fees to be paid by both pharmaceutical manufacturers from 2011 and medical device companies from 2013.
The impact of these recent changes to US healthcare legislation, and other healthcare reforms in the rest of the world, has not to date had a material impact on the Companys results of operations.
24 Shire plc Annual Report 2012 Review of our business The healthcare industry is also experiencing: R&D Over the last five years Shire has focused its R&D efforts on Q pressure from governments and healthcare providers to keep products in its core therapeutic areas and concentrated its prices low while increasing access to drugs: resources on obtaining regulatory approval for later stage pipeline products within these core therapeutic areas.
In addition to Q increasing challenges from third party payors for products continued efforts in its late stage pipeline for the ADHD, GI, HGT to have demonstrable clinical benefit, with pricing and and RM therapeutic areas, Shire has also progressed work on an reimbursement approval becoming increasingly linked to a earlier stage pipeline.
products clinical effectiveness and impact on overall costs of patient care: Evidence of the successful progression of the late stage pipeline can be seen in the granting of approval and associated launches of Q increased R&D costs, because development programs are the Companys products over the last five years.
In this time several typically larger and take longer to get approval from regulators: products have received regulatory approval including: in the US, Q challenges to existing patents from generic manufacturers: INTUNIV in 2009, VPRIV in 2010, and FIRAZYR in 2011: in the EU, VPRIV in 2010 and ELVANSE TYVENSE in 2012: in Canada, Q governments and healthcare systems favoring earlier entry of low VYVANSE in 2010 and DERMAGRAFT in 2012. cost generic drugs: and Shires strategy is focused on the development of product Q higher marketing costs, due to increased competition for candidates that have a lower risk prole.
As Shire further expanded market share.
its earlier phase pipeline, R&D costs in 2012 included expenditure Shires strategy has been developed to address these industryon several preclinical to Phase 3 studies for products in development wide competitive pressures.
This strategy has resulted in a series of as well as Phase 3 b and Phase 4 studies to support recently initiatives in the following areas: launched products in the SP and HGT businesses, together with the development of new projects in the SP, HGT and Markets RM businesses.
Historically, Shires portfolio of approved products has been heavily weighted towards the North American market.
The acquisition in Patents and Market Exclusivity 2005 of TKT and the consequent establishment of the Companys The loss or expiration of patent protection or regulatory exclusivity HGT business, together with the acquisitions of New River with respect to any of the Companys major products could have a Pharmaceuticals in 2007 which brought full rights to ADHD material adverse effect on the Companys revenues, financial product VYVANSE, Jerini AG Jerini in 2008 which brought the condition and results of operations, as generic products may enter HAE product FIRAZYR, EQUASYM in 2009 which facilitated the market.
Companies selling generic products often do not need Shires immediate access to the European ADHD market and to complete extensive clinical studies when they seek registration Movetis NV Movetis in 2010 which brought EU rights to of a generic or biosimilar product and accordingly, they are generally RESOLOR.
The acquisition of ABH in 2011 which subsequently able to sell the Companys products at a much lower price.
became RM, and FerroKin Biosciences in 2012 which brought a As expected, in 2009 Teva and Impax commenced commercial new hematology drug to the SP portfolio provided Shire with shipments of their authorized generic versions of ADDERALL XR, platforms to increase its presence in Europe and the rest of the which led to lower sales of branded ADDERALL XR compared to world RoW, thereby working towards diversifying the risk the period prior to the authorized generic launch.
In June 2012 the associated with reliance on one geographic market.
In 2012 the SP FDA reached a decision on the Citizen Petition for ADDERALL XR and HGT businesses derived 15% and 75%, respectively, of their which was led in October 2005.
The FDA also approved an ANDA product sales from outside of the US.
Currently all RM product for a generic version of ADDERALL XR.
Sales of AXR decreased in sales are generated in the US.
Shire has ongoing commercialization 2012 due to the launch of a new generic product.
and late stage development activities, which are expected to further supplement the diversication of revenues in the future, In 2011 authorized generic and generic versions of the Companys including the following: CARBATROL and REMINYL products respectively were launched, which led to lower sales of these branded products compared to Q continued launch of VYVANSE in Brazil marketed as VENVANSE the period before loss of exclusivity.
and the potential approval and launch of VYVANSE in Mexico: Shire is engaged in various legal proceedings with generic Q approval of ELVANSE TYVENSE in certain countries in the EU manufacturers with respect to its VYVANSE, INTUNIV, FOSRENOL, for treatment of ADHD in children: LIALDA and ADDERALL XR patents.
For more detail of current Q ling in 2012 of an application to expand the label of FIRAZYR in patent litigation, see Note 18 Commitments and contingencies.
the EU to include the treatment of attacks of ACE-inhibitor induced Angioedema: Q ling in 2012 of an application in Europe for the VPRIV label to be updated with data regarding the impact of VPRIV on certain parameters of bone disease in Type 1 Gaucher patients: Q INTUNIV Phase 3 clinical program to support submission of an MAA in the EU: and Q continued roll-out of DFU in Canada and RESOLOR in the EU.
Shire plc Annual Report 2012 25 Financial review Business Development Results of operations for the years to Shire seeks to focus its business development activity on the December 31, 2012 acquisition and in-licensing of products which offer a good Financial highlights for the year to December 31, 2012 are as strategic t and have the potential to deliver demonstrable value to follows: all of the Companys stakeholders.
Q Product sales in 2012 were up 12% to $4,407 million 2011: Recent mergers or acquisitions 1 $3,950 million.
On a Constant Exchange Rate CER basis, In 2012 Shire acquired FerroKin Biosciences Inc. which added which is a Non GAAP measure, product sales were up 13%.
SPD602 to the SP business unit SDP602 is in Phase 2 for treatment of iron overload following numerous blood transfusions.
Product sales excluding ADDERALL XR grew strongly and were up 16% particularly driven by growth from VYVANSE up 28% to Through the acquisition of ABH in 2011 Shire obtained $1,030 million, VPRIV up 20% to $307 million, INTUNIV up 29% DERMAGRAFT, which is currently marketed in the US for the to $288 million and FIRAZYR up 252% to $116 million.
treatment of DFU, and established the RM business unit.
In 2012 Shire acquired substantially all the assets and certain liabilities of ADDERALL XR product sales were down 19% to $429 million Pervasis Therapeutics Inc. which added VASCUGEL now primarily due to lower prescription volumes following the approval SRM003 to the RM business unit SRM003 is in Phase 2 of a new generic version of ADDERALL XR in the second quarter development for acute vascular repair.
Reported product sales were also impacted by the accounting for the settlement of the Impax Laboratories, Inc.
Through the acquisition of Movetis in 2010, Shire obtained Impax litigation see Note 18 Commitments and contingencies RESOLOR, which is approved for the treatment of chronic for further details.
constipation in women in the EU and Switzerland.
In addition, in 2012 Shire acquired the rights to market RESOLOR in the US.
Q Total revenues increased by 10% up 12% on a Non GAAP CER basis as the growth in product sales was partially offset by lower Collaboration and licensing activity royalties and other revenues down 12%, primarily ADDERALL Shire has also entered into a number of collaboration and license XR royalties following the launch of a new generic competitor in agreements, including: the second quarter of 2012.
The decline in ADDERALL XR Q a collaboration and license agreement with Sangamo to develop royalties was partially offset by the recognition of one-time royalty therapeutics for hemophilia and other monogenic diseases income of $38 million following resolution of a disagreement with based on Sangamos ZFP technology in 2012: GSK and ViiV relating to royalty payments for 3TC and ZEFFIX.
Q an exclusive license in markets outside of North America for the Q Operating income in 2012 was down 14% to $949 million 2011: ActRIIB class of molecules being developed by Acceleron in $1,109 million primarily resulting from charges to impair 2010.
The collaboration with Acceleron will initially focus on intangible assets for RESOLOR in the EU $198 million.
The further developing HGT4510 also called ACE031 for the impairments were due to lower actual and projected treatment of patients with DMD: performance for the product given the increasingly challenging European reimbursement environment.
Operating income in Q a worldwide exclusive license from IGAN Biosciences, Inc. 2012 was also impacted by a charge of $58 million in relation to IGAN to develop and commercialize protease-based the agreement in principle with the US Government to resolve a therapeutics for the treatment of IgA nephropathy, a rare previously disclosed civil investigation.
Further information about kidney disease: litigation proceedings can be found in Note 18 Commitments Q Shionogi co-development and co-commercialization agreement and contingencies.
Excluding these charges operating income in for VYVANSE and INTUNIV in Japan.
Organization and Structure Q Diluted earnings per Ordinary Share decreased by 13% to $1.31 Shires internal financial reporting is in line with its business unit and 2011: $1.51 primarily due to the lower operating income, partially management reporting structure.
The Company has three offset by a lower effective tax rate of 18% 2011: 21%.
business units and three reporting segments: SP, HGT and RM.
1 The Companys management analyzes product sales and revenue growth for certain During 2010, to support the Companys geographical expansion products sold in markets outside of the US on a constant exchange rate CER and diversication, Shire established an international commercial basis, so that product sales and revenue growth can be considered excluding hub in Switzerland.
movements in foreign exchange rates.
Product sales and revenue growth on a CER basis is a Non GAAP financial measure Non GAAP CER, computed by comparing On January 23, 2013 Shire announced that it had decided to 2012 product sales and revenues restated using 2011 average foreign exchange proceed with a collective dismissal and business closure at its site rates to 2011 actual product sales and revenues.
This Non GAAP financial measure is used by Shires management, and is considered to provide useful information to in Turnhout, Belgium.
This decision follows the conclusion of an investors about the Companys results of operations, because it facilitates an information and consultation process.
Shire will continue to sell evaluation of the Companys year on year performance on a comparable basis.
RESOLOR in Europe and the supply of RESOLOR for patients in Average exchange rates for the year to December 31, 2012 were $1.59:1.00 and Europe who rely on the medicine will not be affected.
The collective $1.29:1.00 2011: $1.60:1.00 and $1.39:1.00. dismissal and business closure of the Turnhout site is not expected to have a material impact on the Companys consolidated financial position and results of operations in future periods.
Exit market share represents the average US market share in the month ended December 31, 2012.
2 IMS NPA Data not available.
3 Not sold in the US in the year to December 31, 2012.
4 DERMAGRAFT was acquired by Shire on June 28, 2011 sales growth above reects full year 2012 sales compared to post acquisition sales for 2011.
Shire plc Annual Report 2012 27 Financial review PENTASA Ulcerative colitis Specialty Pharmaceuticals PENTASA product sales were up 6% as the benefit of price VYVANSE ADHD increases was partially offset by lower prescription demand, a small VYVANSE product sales grew strongly 28% in 2012 as a result of amount of destocking in 2012 and higher sales deductions as higher prescription demand, due to growth in US ADHD market compared to 2011.
9% and VYVANSEs share of that market, and as a result of a price increase taken in 2012.
These positive factors, together with FOSRENOL Hyperphosphatemia lower sales deductions in 2012, more than offset the effect of Product sales of FOSRENOL in the US increased 3% due to the higher retailer destocking in 2012 compared to 2011 and some effect of price increases in 2012 and lower sales deductions shipment slippage at the end of the fourth quarter.
compared to 2011, which more than offset the decline in prescription demand.
Product sales of FOSRENOL outside the US Litigation proceedings regarding VYVANSE are ongoing.
Further decreased marginally primarily because of the impact of information about this litigation can be found in Note 18 unfavorable foreign exchange.
Litigation proceedings regarding Shires FOSRENOL patents are ADDERALL XR ADHD ongoing.
Further information about this litigation can be found in ADDERALL XR product sales decreased -19% in 2012 as a result Note 18 Commitments and contingencies.
of lower US prescription demand following the introduction of a new generic competitor and the impact of the accounting for the Human Genetic Therapies legal settlement with Impax, which reduced reported product sales by $42 million in 2012, in addition to the effect of product ELAPRASE Hunter syndrome destocking in 2012 compared to stocking in 2011 and, higher sales Reported ELAPRASE sales growth 7% was driven by an increase deductions.
These negative factors were partially offset by the in the number of patients on therapy.
On a Non GAAP CER basis, benefit of a price increase taken during 2012.
ELAPRASE sales grew by 11% as reported sales were held back by unfavorable foreign exchange amounting to approximately $20 On February 7, 2013 Shire and Impax settled all litigation relating to million primarily due to weaker European currencies in 2012 Shires contract to supply Impax with authorized generic compared to 2011.
The increase in ELAPRASE sales between the ADDERALL XR.
Under the terms of the settlement Shire will make third quarter and fourth quarter of 2012 was partly driven by the a one-time cash payment to Impax of $48 million, which has been timing of certain large orders from markets which order less recorded as a liability at December 31, 2012.
US GAAP, as this represents a payment to a customer, the amount has been recorded in the Income Statement as a reduction in REPLAGAL Fabry disease reported ADDERALL XR product sales and royalties $42 million Reported REPLAGAL sales growth 5% was driven by an increase and $6 million respectively in 2012. in the number of patients on therapy.
On a Non GAAP CER basis, REPLAGAL sales grew by 10%, as reported sales were impacted Further information about litigation proceedings regarding by unfavorable foreign exchange amounting to approximately $26 ADDERALL XR, and the Impax settlement, can be found in Note 18 million, primarily due to weaker European currencies in 2012 Commitments and contingencies.
The reduction in REPLAGAL sales between the INTUNIV ADHD third and fourth quarter of 2012 was partly driven by the timing of INTUNIV product sales were up 29% compared to 2011, primarily certain large orders from markets which order less frequently.
driven by strong growth in US prescription demand up 34% Litigation proceedings regarding REPLAGAL are ongoing.
Further compared to 2011, together with price increases taken during information about this litigation can be found in Note 18 2012.
These positive factors were partially offset by lower stocking Commitments and contingencies.
in 2012 and higher sales deductions in 2012 compared to 2011.
VPRIV Gaucher disease Litigation proceedings relating to the Companys INTUNIV patents Reported VPRIV sales growth 20% was driven by an increase in are in progress.
For further information see Note 18 Commitments the number of patients on therapy.
On a Non GAAP CER basis, and contingencies.
VPRIV sales increased by 23% as reported sales were also held LIALDA MEZAVANT Ulcerative colitis back by unfavorable foreign exchange amounting to approximately The growth in product sales for LIALDA MEZAVANT 7% in 2012 $8 million.
was primarily driven by higher market share in the US and a price FIRAZYR HAE increase taken since the fourth quarter of 2011, the effects of which Reported FIRAZYR sales growth 252% was driven largely by the were partially offset by product destocking in 2012 compared to a first full year of sales in the US market, following launch of FIRAZYR small amount of product stocking in 2011 and higher sales in the market in fourth quarter of 2011. deductions in 2012.
Growth in US net product sales was partially offset by the impact of lower priced imports into certain European markets.
Regenerative Medicine DERMAGRAFT DFU Litigation proceedings regarding LIALDA MEZAVANT are ongoing.
1 DERMAGRAFT product sales were up 46% compared to sales Further information about this litigation can be found in Note 18 reported by Shire subsequent to acquisition in 2011.
On a full year Commitments and contingencies.
basis, sales for DERMAGRAFT were down 21% reecting the impact of an ongoing restructuring of the RM sales and marketing organization and the implementation of a new commercial model, all of which is expected to position DERMAGRAFT for future sales growth.
1 Shire acquired DERMAGRAFT through its acquisition of ABH on June 28, 2011 and reported revenues from DERMAGRAFT of $105.3m relating to the post acquisition period in 2011.
28 Shire plc Annual Report 2012 Review of our business Royalties SG&A Year to Year to SG&A expenditure increased to $2,114.0 million 48% of product December 31, December 31, 2012 $M 2011 $M Change % sales for the year to December 31, 2012 from $1,751.4 million 44% of product sales in the corresponding period in 2011.
In the year to 3TC and ZEFFIX 91.6 82.7 11% December 31, 2012 SG&A increased by $362.6 million, or 21%, as ADDERALL XR 70.3 107.1 -34% 2012 included higher intangible asset amortization, the impact of FOSRENOL 53.3 46.5 15% impairment charges and higher legal and litigation costs, which Other 26.4 47.2 -44% included a charge of $57.5 million in relation to the agreement in Total 241.6 283.5 -15% principle with the US Government and settling the litigation related to the termination of co-promotion agreement for VYVANSE.
Royalties from 3TC and ZEFFIX include one-time royalty income of Impairment charges of $126.7 million relate to RESOLOR intangible $38 million in respect of prior periods due to resolution of the assets as the actual and projected performance for RESOLOR has disagreement between Shire, GSK and ViiV as to how the royalty been adversely affected by the challenging European rate for these products should be applied.
This one-time income reimbursement environment.
Shire has evaluated alternative sales more than offset the underlying decline in 3TC and ZEFFIX royalties and marketing strategies for RESOLOR in response to these as a result of increased competition and the expiry of patents in challenges but has judged that projected profitability levels will certain territories in 2012. continue to be below the level forecast at the time of the acquisition of Movetis.
Royalties from ADDERALL XR in 2012 were signicantly impacted by the lower royalty rate payable on sales of authorized generic For the year to December 31, 2012 SG&A included depreciation of ADDERALL XR by Impax, following the launch of a new generic $59.8 million 2011: $63.1 million and amortization of $194.1 million version of ADDERALL XR in late second quarter of 2012.
FOSRENOL royalties increased primarily due to higher royalties received on sales in Japan.
Gain loss on sale of product rights Other royalties decreased primarily due to increased generic For the year to December 31, 2012 Shire recorded a gain on sale of competition.
product rights of $18.1 million 2011: loss of $6.0 million following re-measurement of the contingent consideration receivable from the divestment of DAYTRANA.
Cost of product sales Cost of product sales increased to $645.4 million for the year to Integration and acquisition costs December 31, 2012 15% of product sales, up from $588.1 million For the year to December 31, 2012 Shire recorded integration and in the corresponding period in 2011 2011: 15% of product sales.
acquisition costs of $25.2 million 2011: $13.7 million, primarily The costs of product sales as a percentage of product sales associated with the acquisition of FerroKin and the integration of remained constant as the impact of lower gross margins in 2012 ABH.
In 2011 integration and acquisition costs primarily related to was offset by the fair value adjustment relating to DERMAGRAFT the acquisition of ABH.
inventories and costs incurred on the transfer of manufacturing from Owings Mills in 2011 which were not repeated in 2012.
Interest expense For the year to December 31, 2012 cost of product sales included depreciation of $31.5 million 2011: $39.8 million and amortization For the year to December 31, 2012 Shire incurred interest expense of $0.7 million 2011: $1.7 million.
Interest expense principally relates to the coupon and amortization of issue costs on Shires R&D $1,100 million 2.75% convertible bonds due 2014.
R&D expenditure increased to $965.5 million for the year to December 31, 2012 22% of product sales, compared to $770.7 Taxation million in the corresponding period in 2011 20% of product sales.
The effective In the year to December 31, 2012 R&D included up-front payment tax rate in 2012 is lower than 2011 due to favorable changes in profit of $13.0 million to Sangamo, $10.0 million to acquire the US rights mix in 2012 and the benefit of the recognition of foreign tax credits.
for prucalopride marketed in certain countries in Europe as RESOLOR and IPR&D impairment charges in respect of RESOLOR of $71.2 million 2011: $16.0 million.
Excluding these Financial condition at December 31, 2012 costs R&D increased by $100.6 million or 20% in the year to Cash and cash equivalents December 31, 2012 due to the Companys continued investment in Cash and cash equivalents increased by $862.2 million to $1,482.2 a number of targeted R&D programs, particularly new uses of LDX million December 31, 2011: $620.0 million.
Cash generated by and recently acquired assets including SPD602 for iron overload operating activities of $1,382.9 million was offset by the cost of acquired with FerroKin.
R&D in 2012 also included a full year of acquiring FerroKin, other capital expenditure, the purchase of ABHs R&D costs ABH was acquired in late June 2011. shares both by the employee benefit trust EBT and under the share buy-back program and dividend payments.
R&D in the year to December 31, 2012 included depreciation of $22.5 million 2011: $25.2 million.
Shire plc Annual Report 2012 29 Financial review Other intangible assets, net Shire.
On April 9, 2012 the deadline for Bondholders to choose to Other intangible assets have decreased by $104.9 million to exercise the Put Option passed.
No elections from the $2,388.1 million December 31, 2011: $2,493.0 million.
Additions in Bondholders were received by this date and the Bonds are now the year of $281.6 million, principally relating to intangible assets due on the Final Maturity date.
In addition, Shire has a revolving acquired with FerroKin and from Pervasis and the license acquired credit facility of $1,200 million which matures in 2015 the RCF, from Mt.
Sinai School of Medicine of New York University, were which is currently undrawn.
offset by intangible asset amortization and impairment charges of Shire 2.75% Convertible Bonds due 2014 $194.8 million and $197.9 million respectively.
On May 9, 2007 Shire issued the Bonds and the net proceeds of Accounts payable and accrued expenses the issuance, after deducting the commissions and other direct Accounts payable and accrued expenses have increased by costs of issue, totaled $1,081.7 million.
In connection with the $131.0 million to $1,501.5 million December 31, 2011: $1,370.5 Scheme the Trust Deed was amended and restated in 2008 in million mainly due to the recognition of liabilities in relation to the order to provide that, following the substitution of Shire plc in place settlement of litigation with Impax Laboratories Inc. and the of Old Shire as the principal obligor and issuer of the Bonds, the agreement in principle reached with the US Government regarding Bonds would be convertible into ordinary shares of Shire plc.
the investigation into the sales and marketing of ADDERALL XR, The Bonds were issued at 100% of their principal amount, and DAYTRANA and VYVANSE.
unless previously purchased and canceled, redeemed or Convertible bonds converted, will be redeemed on May 9, 2014 the Final Maturity Convertible bonds current liabilities have decreased by $1,100 Date at their principal amount.
million due to the reclassication of the Companys $1,100 million The Bonds bear interest at 2.75% per annum, payable semi- 2.75% convertible bonds due 2014 and convertible into fully paid annually in arrears on November 9 and May 9.
The Bonds ordinary shares of Shire plc the Bonds from current to nonconstitute direct, unconditional, unsubordinated and unsecured current liabilities in 2012 as the Company is no longer required to obligations of the Company, and rank pari passu and ratably, redeem the Bonds within twelve months of the balance sheet date.
without any preference amongst themselves, and equally with all See Note 16 for further details.
other existing and future unsecured and unsubordinated Other non-current liabilities obligations of the Company.
Other non-current liabilities increased by $97.3 million to $241.6 The Bonds may be redeemed at the option of the Company, at million December 31, 2011: $144.3 million due primarily to the their principal amount together with accrued and unpaid interest if: recognition of non-current contingent consideration payable i at any time after May 23, 2012 if on no less than 20 dealing days totaling $120.4 million related to the FerroKin and Pervasis business in any period of 30 consecutive dealing days the value of Shires combinations and the license agreement with Mt.
Ordinary Shares underlying each Bond in the principal amount of $100,000 would exceed $130,000: or ii at any time conversion Liquidity and capital resources rights have been exercised, and or purchases and corresponding cancellations, and or redemptions effected in respect of 85% or General more in principal amount of Bonds originally issued.
The Bonds are The Companys funding requirements depend on a number of repayable in US dollars, but also contain provisions entitling the factors, including the timing and extent of its development Company to settle redemption amounts in Pounds sterling, or programs: corporate, business and product acquisitions: the level in the case of the Final Maturity Date or any change of control of resources required for the expansion of certain manufacturing Shire, by delivery of the underlying ordinary shares and a cash and marketing capabilities as the product base expands: increases top-up amount.
in accounts receivable and inventory which may arise with any increase in product sales: competitive and technological The Bonds are convertible into ordinary shares during the developments: the timing and cost of obtaining required regulatory conversion period, being the period from June 18, 2007 until the approvals for new products: the timing and quantum of milestone earlier of: i the close of business on the date falling fourteen days payments on collaborative projects: the timing and quantum of tax prior to the Final Maturity Date: ii if the Bonds have been called for and dividend payments: the timing and quantum of purchases by redemption by the Company, the close of business fourteen days the EBT of Shire shares in the market to satisfy awards granted before the date xed for redemption: iii the close of business on under Shires employee share plans: the timing and quantum of the day prior to a Bond holder giving notice of redemption in purchases of Shire shares under the share buy-back program: and accordance with the conditions: and iv the giving of notice by the the amount of cash generated from sales of Shires products and trustee that the Bonds are accelerated by reason of the occurrence royalty receipts.
An important part of Shires business strategy is to protect its Upon conversion, the Bond holder is entitled to receive Ordinary products and technologies through the use of patents, proprietary Shares at the conversion price of $32.83 per ordinary share, technologies and trade marks, to the extent available.
The subject to adjustment as outlined below.
Company intends to defend its intellectual property and as a result may need cash for funding the cost of litigation.
The conversion price is subject to adjustment in respect of i any dividend or distribution by the Company, ii a change of control The Company nances its activities through cash generated from and iii customary anti-dilution adjustments for, inter alia, share operating activities: credit facilities: private and public offerings consolidations, share splits, spin-off events, rights issues, bonus of equity and debt securities: and the proceeds of asset or issues and reorganizations.
The initial conversion price of $33.5879 investment disposals.
was adjusted to $33.17 with effect from March 11, 2009 as a result of cumulative dividend payments during the period from October Shires balance sheet includes $1,482.2 million of cash and cash 2007 to April 2009 inclusive, and was further adjusted to $32.83 equivalents at December 31, 2012.
Substantially all of Shires debt with effect from March 11, 2011 as a result of cumulative dividend relates to its $1,100 million 2.75% convertible bonds due 2014 the payments during the period April 2009 to April 2011 inclusive.
The Bonds were potentially redeemable at the option of Ordinary Shares issued on conversion will be delivered credited as Bondholders at their principal amount including accrued and fully paid, and will rank pari passu in all respects with all fully paid unpaid interest on May 9, 2012 the Put Option, and remain Ordinary Shares in issue on the relevant conversion date.
redeemable following the occurrence of a change of control of 30 Shire plc Annual Report 2012 Review of our business Revolving Credit Facilities Agreement the authority renewed by shareholders at the Companys AGM on On November 23, 2010 the Company entered into a committed April 24, 2012 when the Company was authorized to make market multicurrency revolving and swingline facilities agreement with a purchases of up to 56,253,208 of its own Ordinary Shares.
That number of financial institutions, for which Abbey National Treasury authority will expire at the 2013 AGM and in accordance with usual Services Plc trading as Santander Global Banking and Markets, practice a resolution to renew it for another year will be proposed.
Bank of America Securities Limited, Barclays Capital, Citigroup Sources and uses of cash Global Markets Limited, Lloyds TSB Bank plc and The Royal Bank The following table provides an analysis of the Companys gross of Scotland plc acted as mandated lead arrangers and and net debt excluding restricted cash, as at December 31, 2012 bookrunners the new RCF.
The new RCF is for an aggregate and 2011: amount of $1,200 million and canceled the Companys then existing committed revolving credit facility the old RCF.
The new RCF, 2012 2011 December 31, $M $M which includes a $250 million swingline facility, may be used for general corporate purposes and matures on November 23, 2015.
1 Cash and cash equivalents 1,482.2 620.0 The interest rate on each loan drawn under the new RCF for each Shire 2.75% Convertible bonds 1,100.0 1,100.0 interest period is the percentage rate per annum which is the Other debt 9.3 8.2 aggregate of the applicable margin ranging from 0.90 to 2.25 per Total debt 1,109.3 1,108.2 cent per annum and LIBOR for the applicable currency and interest period.
Shire also pays a commitment fee on undrawn Net cash debt 372.9 488.2 amounts at 35 per cent per annum of the applicable margin.
1 Substantially all of the Companys cash and cash equivalents are held by foreign subsidiaries, i. e. those subsidiaries incorporated outside of Jersey, Channel Islands, Under the new RCF it is required that i Shires ratio of Net Debt to the jurisdiction of incorporation of Shire plc, Shires holding company.
The amount of EBITDA as dened within the new RCF agreement does not cash and cash equivalents held by foreign subsidiaries has not had, and is not exceed 3.5 to 1 for either the 12 month period ending December expected to have, a material impact on the Companys liquidity and capital resources.
31 or June 30 unless Shire has exercised its option which is Cash flow activity subject to certain conditions to increase it to 4.0 to 1 for two Net cash provided by operating activities for the year to December consecutive testing dates: ii the ratio of EBITDA to Net Interest as 31, 2012 increased by $309.3 million or 29% to $1,382.9 million dened in the new RCF agreement must not be less than 4.0 to 1, 2011: $1,073.6 million as higher cash receipts from gross product for either the 12 month period ending December 31 or June 30, sales and improved cash collections for aged European receivables and iii additional limitations on the creation of liens, disposal of more than offset higher operating expenses and sales deduction assets, incurrence of indebtedness, making of loans, giving of payments in the year.
guarantees and granting security over assets.
These financial and operating covenants have not had, and are not expected to have, Net cash used in investing activities was $271.0 million in the year an effect on the Companys financial position and liquidity.
to December 31, 2012, principally relating to the expenditure on property, plant and equipment of $149.6 million and the cash paid On entering into the new RCF in November 2010 the Company paid net of cash acquired of $97.0 million for the acquisition of FerroKin arrangement costs of $8.0 million, which have been recorded as $94.5 million and Pervasis $2.5 million.
Capital expenditure on deferred charges, with amortization of these costs to the Companys property, plant and equipment primarily includes expenditure of income statement over the contractual term of the new RCF.
$65.0 million on computer software and hardware due to SAP The availability of loans under the new RCF is subject to upgrade and construction and leasehold improvements at different customary conditions.
Financing Net cash used in nancing activities was $244.3 million for the year Shire anticipates that its operating cash ow together with available to December 31, 2012, principally due to the purchase of shares by cash, cash equivalents and the RCF will be sufficient to meet its the EBT, the purchase of shares under the share buy-back anticipated future operating expenses, share buy-back program, program and dividend payments, offset by the tax benefit capital expenditures, tax and interest payments, lease obligations associated with the exercise of stock options.
and milestone payments as they become due over the next Outstanding Letters of credit twelve months.
At December 31, 2012, the Company had irrevocable standby If the Company decides to acquire other businesses, it expects letters of credit and guarantees with various banks totaling $38.2 to fund these acquisitions from existing cash resources, the RCF million, providing security for the Companys performance of and possibly through new borrowings and the issue of new equity various obligations.
These obligations are primarily in respect of the if necessary.
recoverability of insurance claims, lease obligations and supply commitments.
Share buy-back program Shire has a strong balance sheet and continued robust cash generation, and considers efficient use of capital on behalf of shareholders an important objective.
Therefore, during the year to December 31, 2012 the Company commenced a share buy-back program, for the purpose of returning funds to shareholders, of up to $500 million through both direct purchases of Ordinary Shares and through the purchase of Ordinary Shares underlying ADRs.
During the year ended December 31, 2012 the Company made on-market repurchases totaling 3,631,571 Ordinary Shares at a cost of $106.4 million excluding transaction costs.
This represents 0.65% of the issued share capital of the Company as at the year end.
The program covers purchases of Ordinary Shares for cancelation or to be held as treasury shares, in accordance with Shire plc Annual Report 2012 31 Financial review Cash requirements At December 31, 2011 the Groups cash requirement for long term liabilities reected on the balance sheet and other contractual obligations were as follows: Payments due by period Less than More than Total 1 year 1 3 years 3 5 years 5 years $M $M $M $M $M i Convertible bonds 1,145.4 30.3 1,115.1 ii Operating leases obligation 244.3 49.6 61.0 40.8 92.9 iii Purchase obligations 806.8 670.1 127.7 4.4 4.6 iv Other long term liabilities reected on the Balance Sheet 230.2 159.3 37.8 33.1 Total 2,426.7 750.0 1,463.1 83.0 130.6 i Shires $1,100 million principal amount of 2.75% convertible bonds due 2014 and the interest on the Bonds has been included based on their contractual payment dates.
The principal amount of $1,100 million has been included within payments due in one to three years based on the Final Maturity Date of the Bonds.
On April 9, 2012 the deadline for Bondholders to choose to exercise their Put Option on May 9, 2012 passed.
No elections from the Bondholders were received by this date and the Bonds are now due on the Final Maturity Date, subject to the certain exceptions.
As the Company is no longer required to redeem the Bonds within twelve months of the balance sheet date, the Bonds have been presented as a non-current liability at December 31, 2012.
Further details are included within Liquidity and capital resources: Shire 2.75% Convertible Bonds due 2014 above.
ii The Company leases certain land, facilities, motor vehicles and certain equipment under operating leases expiring through 2021. iii Purchase obligations include agreements to purchase goods, investments or services including clinical trials, contract manufacturing and capital equipment, including open purchase orders, that are enforceable and legally binding and that specify all significant terms.
Shire expects to fund these commitments with cash ows from operating activities.
iv Unrecognized tax benets and associated interest and penalties of $58.9 million are included within payments due in one to three years.
The contractual obligations table above does not include certain milestones and other contractual commitments where payment is contingent upon the occurrence of events which are yet to occur and therefore payment is not yet due.
At December 31, 2012 the most significant of the Companys milestone and contractual commitments which are contingent on the occurrence of future events are as follows: i Collaboration with Acceleron for ActRIIB class of molecules ii Research Collaboration with Santaris Pharma A S On September 9, 2010 Shire announced that it had expanded its Santaris on Locked Nucleic Acid LNA Drug Platform HGT pipeline by acquiring an exclusive license in markets outside On August 24, 2009 Shire announced that it had entered into a of North America for the ActRIIB class of molecules being research collaboration with Santaris, to develop its proprietary LNA developed by Acceleron.
The collaboration will initially focus on technology in a range of rare diseases.
LNA technology has the further developing HGT4510 also called ACE031, the lead ActRIIB benefit of shortened target validation and proof of concept, drug candidate, which is in development for the treatment of potentially increasing the speed and lowering the cost of patients with Duchenne muscular dystrophy DMD.
As part of the joint research project Santaris will 2a trial is on hold and clinical safety is under review.
HGT4510 and design, develop and deliver preclinical LNA oligonucleotides for the other ActRIIB class of molecules have the potential to be used Shire-selected orphan disease targets, and Shire will have the in other muscular and neuromuscular disorders with high unmet exclusive right to further develop and commercialize these medical need.
candidate compounds on a worldwide basis.
In the year to December 31, 2010 Shire made an up-front payment In the year to December 31, 2009 Shire made an up-front payment of $45 million to Acceleron which has been expensed to R&D.
to Santaris of $6.5 million, for technology access and R&D funding, which was expensed to R&D.
In the year to December 31, 2012 Shires share of R&D costs under this collaboration agreement was $4.5 million 2011: $10.1 million: In the year to December 31, 2012 Shire paid success milestones 2010: $2.7 million which were expensed to R&D.
Shire will pay and other support costs of $3.0 million 2011: $2.5 million: 2010: Acceleron up to a further $165.0 million, subject to certain $4.0 million and $8.1 million 2011: $5.3 million: 2010: $2.3 million development, regulatory and sales milestones being met for to Santaris respectively, which were expensed to R&D.
Shire has HGT4510 in DMD, up to an additional $288 million for successful remaining obligations to pay Santaris $13.5 million subject to commercialization of other indications and molecules, and royalties certain success criteria, and development and sales milestones on product sales.
up to a maximum of $69.0 million for each indication.
Shire will also pay single or double digit tiered royalties on net sales of Shire and Acceleron will conduct the collaboration through a joint the product.
steering committee, with subcommittees including a joint manufacture committee, and a joint patent committee to monitor Shire and Santaris have formed a joint research committee to the development of HGT4510 and other compounds.
monitor R&D activities through preclinical lead candidate selection at which point all development and commercialization costs will be the responsibility of Shire.
32 Shire plc Annual Report 2012 Review of our business iii Collaboration and license agreement with Sangamo to Treasury policies and organization develop therapeutics for hemophilia The Companys principal treasury operations are coordinated by its On February 1, 2012 Shire and Sangamo announced that they had corporate treasury function.
All treasury operations are conducted entered into a collaboration and license agreement to develop within a framework of policies and procedures approved annually therapeutics for hemophilia and other monogenic diseases based by the Board of Directors.
As a matter of policy, the Company does on Sangamos ZFP technology.
Sangamo is responsible for all not undertake speculative transactions that would increase its activities through submission of Investigational New Drug credit, currency or interest rate exposure.
Applications and European Clinical Trial Applications for each product and Shire will reimburse Sangamo for its internal and external research program-related costs.
Shire is responsible for Interest rate risk clinical development and commercialization of products arising The Company is exposed to interest rate risk on restricted cash, from the collaboration.
cash and cash equivalents and on foreign exchange contracts on which interest is at oating rates.
This exposure is primarily to US In the year to December 31, 2012 Shire made an up-front payment Dollar, Pounds Sterling, Euro and Canadian Dollar interest rates.
As to Sangamo of $13.0 million, for technology access and R&D the Company maintains all of its cash, liquid investments and funding, which was expensed to R&D.
foreign exchange contracts on a short term basis for liquidity In the year to December 31, 2012 Shires share of R&D costs under purposes, this risk is not actively managed.
In the year to this collaboration agreement was $8.9 million 2011: $nil: 2010: $nil December 31, 2012 the average interest rate received on cash and which were expensed to R&D.
Shire may be required to pay liquid investments was less than 1% per annum.
The largest research, regulatory, development and commercial milestone proportion of these cash and liquid investments was in US dollar payments up to a maximum of $213.5 million and to pay royalties money market and liquidity funds.
on net sales of the product.
The Company incurs interest at a xed rate of 2.75% on its $1,100 iv Acquisition of FerroKin million in principal amount convertible bonds due 2014.
On April 2, 2012 Shire completed the acquisition of 100% of the No derivative instruments were entered into during the year to outstanding share capital of FerroKin.
The acquisition-date fair December 31, 2012 to manage interest rate exposure.
The value of consideration totaled $159.3 million, comprising cash Company continues to review its interest rate risk and the policies consideration paid on closing of $94.5 million and the fair value of in place to manage the risk.
contingent consideration payable of $64.8 million.
The maximum amount of contingent cash consideration which may be payable by Shire in future periods is $225.0 million.
The amount of contingent Foreign exchange risk cash consideration ultimately payable by Shire is dependent upon The Company trades in numerous countries and as a the achievement of certain clinical development, regulatory and net consequence has transactional and translational foreign exchange sales milestones.
v Acquisition of certain assets and liabilities of Pervasis Transactional exposure arises where transactions occur in On April 19, 2012 Shire acquired substantially all the assets and currencies different to the functional currency of the relevant certain liabilities of Pervasis.
The acquisition date fair value of the subsidiary.
The main trading currencies of the Company are the US consideration totaled $26.1 million, comprising cash consideration Dollar, Pounds Sterling, Swiss Franc and the Euro.
It is the paid on closing of $2.5 million and the fair value of contingent Companys policy that these exposures are minimized to the extent consideration payable of $23.6 million.
The maximum amount of practicable by denominating transactions in the subsidiarys contingent cash consideration which may be payable by Shire in functional currency.
The amount of contingent cash consideration ultimately payable by Shire is dependent upon Where significant exposures remain, the Company uses foreign achievement of certain clinical development, regulatory and net exchange contracts being spot, forward and swap contracts to sales milestones.
manage the exposure for balance sheet assets and liabilities that are denominated in currencies different to the functional currency of the relevant subsidiary.
These assets and liabilities relate predominantly to intercompany nancing and specic external receivables.
The foreign exchange contracts have not been designated as hedging instruments.
Cash ows from derivative instruments are presented within net cash provided by operating activities in the consolidated cash ow statement, unless the derivative instruments are economically hedging specic investing or nancing activities.
Shire plc Annual Report 2012 33 Financial review Translational foreign exchange exposure arises on the translation Concentration of credit risk into US dollars of the financial statements of non-US dollar Financial instruments that potentially expose Shire to functional subsidiaries.
concentrations of credit risk consist primarily of short term cash At December 31, 2012 the Company had 19 swap and forward investments, derivative contracts and trade accounts receivable foreign exchange contracts outstanding to manage currency risk.
from product sales and from third parties from which the The swaps and forward contracts mature within 90 days.
Cash is invested in short term money Company did not have credit risk related contingent features or market instruments, including money market and liquidity funds collateral linked to the derivatives.
At December 31, 2012 the fair and bank term deposits.
The money market and liquidity funds in value of these contracts was a net liability of $1.7 million.
Further which Shire invests are all triple A rated by both Standard and details are included below.
Poors and by Moodys credit rating agencies.
Foreign exchange risk sensitivity The Company is exposed to the credit risk of the counterparties The following exchange rate sensitivity analysis summarises the with which it enters into derivative instruments.
The Company limits sensitivity of the Companys reported revenues and net income to this exposure through a system of internal credit limits which vary hypothetical changes in the average annual exchange rates of the according to ratings assigned to the counterparties by the major Euro, Pound Sterling and Swiss Franc against the US Dollar, rating agencies.
The internal credit limits are approved by the assuming a hypothetical 10% strengthening of the US Dollar Board and exposure against these limits is monitored by the against each of the aforementioned currencies in the year to corporate treasury function.
The counterparties to these derivatives December 31, 2012 : contracts are major international financial institutions.
Increase Increase The Companys revenues from product sales in the US are mainly reduction in reduction in governed by agreements with major pharmaceutical wholesalers revenues net income and relationships with other pharmaceutical distributors and retail $M $M pharmacy chains.
For the year to December 31, 2012 there were Euro 76 42 three customers in the US that accounted for 50% of the Pound Sterling 22 2 Companys product sales.
However, such customers typically have Swiss Franc 30 significant cash resources and as such the risk from concentration of credit is considered acceptable.
The Company has taken A 10% weakening of the US Dollar against the aforementioned positive steps to manage any credit risk associated with these currencies would have an equal and opposite effect.
transactions and operates clearly dened credit evaluation procedures.
However, an inability of one or more of these wholesalers The table below provides information about the Companys swap to honor their debts to the Company could have an adverse effect on and forward foreign exchange contracts by currency pair.
The table the Companys financial condition and results of operations.
presents the net principal amounts and weighted average exchange rates of all outstanding contracts.
All contracts have a A substantial portion of the Companys accounts receivable in maturity date of less than three months.
countries outside of the United States is derived from product sales to government-owned or government-supported healthcare Principal Weighted providers.
The Companys recovery of these accounts receivable is Value of Average therefore dependent upon the financial stability and Amount Exchange Receivable Rate Fair Value creditworthiness of the relevant governments.
In recent years the December 31, 2012 $M $M creditworthiness and general economic condition of the Relevant Countries has deteriorated.
As a result, in some of these countries Swap foreign the Company is experiencing delays in the remittance of exchange contracts receivables due from government-owned or governmentReceive USD Pay EUR 213.7 1.30 2.8 supported healthcare providers.
Receive GBP Pay USD 117.5 1.61 1.1 Receive USD Pay CAD 7.8 1.01 0.1 Receive USD Pay SEK 9.0 0.15 0.2 Receive USD Pay AUD 2.5 1.04 Receive USD Pay MXN 3.6 0.08 0.1 34 Shire plc Annual Report 2012 Review of our business The Companys aggregate accounts receivable, net of the To date the Company has not incurred significant losses on the allowance for doubtful accounts, in total from government-owned accounts receivable in the Relevant Countries, and continues to or government-supported healthcare providers in the Relevant consider that such accounts receivable are recoverable.
Countries are as follows: Other than the accounts receivable from government-owned or December 31, December 31, supported healthcare providers outlined above, the Company does 2012 2011 not hold any other government debt from the Relevant Countries.
$M $M Additionally the Company does not consider it is currently exposed Total accounts receivable, net in the to significant sovereign credit risk outside of the Relevant Countries.
Relevant Countries 137 184 The Company continues to evaluate all its accounts receivable for Total accounts receivable, net in the potential collection risks and has made provision for amounts Relevant Countries as a percentage of where collection is considered to be doubtful.
If the financial total outstanding accounts receivable, condition of the Relevant Countries or other Eurozone countries net 17% 22% suffer significant deterioration, such that their ability to make Accounts receivable, net due from payments becomes uncertain, or if one or more Eurozone member government-owned or governmentcountries withdraws from the Euro, additional allowances for supported healthcare providers for the doubtful accounts may be required, and losses may be incurred, in Relevant Countries 130 170 future periods.
Any such loss could have an adverse effect on the Companys financial condition and results of operations.
Accounts receivable due from government-owned or governmentsupported healthcare providers in the Relevant Countries of $130 Graham Hetherington million 2011: $170 million are split by country as follows: Greece $6 Chief Financial officer million 2011: $4 million : Ireland $1 million 2011: $1 million : Italy February 25, 2013 $62 million 2011: $81 million : Portugal $13 million 2011: $14 million and Spain $48 million 2011: $70 million.
The Company continues to receive remittances in relation to government-owned or government-supported healthcare providers in the Relevant Countries and in the year to December 31, 2012 received $280.2 million in settlement of accounts receivable in the Relevant Countries $4 million was from Greece: $142.3 million from Italy: $15.2 million from Portugal and $118.7 million from Spain.
